European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
30 Aug 2010

GRACE: Five year outcomes (UK Belgian collaboration) 

 

Topics: Acute Coronary Syndromes (ACS)
Session number: 710009 - 710010
Session title: Clinical Trial Update II
Authors: Fox, Keith - Verheugt, Freek


Professor Keith A. Fox
  Presenter
Presenter | see Discussant report Play presentation webcast
Fox, Keith
(United Kingdom)
Open presentation slides

List of Authors:
Keith A.A. Fox, MB, ChB, FMed Sci, Kathryn F Carruthers MPhil, Donald R Dunbar PhD, Catriona Graham MSc, Jonathan R Manning PhD, Herbert De Raedt MD, Ian Buysschaert MD, PhD, Diether Lambrechts PhD, Frans Van de Werf MD, PhD

Abstract:

Aim:
To define the long-term outcome of patients presenting with acute coronary syndrome (ST elevation myocardial infarction (STEMI), and non-STEMI and unstable angina (ACS without biomarker elevation) and to test the hypothesis that the GRACE risk score predicts mortality and death/MI at 5 years.

Methods and Results:
In the GRACE (Global Registry of Acute Coronary Events) long-term study, UK and Belgian centres prospectively recruited and followed ACS patients for a median of 5 years (1570 days). Primary outcome events: deaths, cardiovascular deaths (CVD) and MIs. Secondary events: stroke and re-hospitalisation for ACS. There were 736 deaths, 19.8% (532 CV deaths, 14.3%) and 347 (9.3%) MIs, (>24hours), 261 strokes (7.7%), and 452 (17%) subsequent revascularisations. Rehospitalisation was common: average 1.6 per patient; 31.2% had >1 admission, 9.2% had 5+ admissions). These events were despite high rates of guideline indicated therapies.
The GRACE score was highly predictive of all cause death, cardiovascular death (CVD), and CVD/MI at 5 years (death: Chi Squared Likelihood Ratio 477.1; Wald 352.6, p<0.0001, C statistic 0.77; for CVD C statistic 0.75, p<0.0001; CVD/MI C statistic 0.68, p<0.0001). Compared with the low risk GRACE stratum, (ESC Guideline criteria), those with intermediate (OR 2.49, 95%CI 1.73, 3.58) and those with high risk (OR 10.09, 95%CI 7.21, 14.13) had a 2.5 and 10-fold higher risk of later death. A landmark analysis after 6-months confirmed that the GRACE score predicted long-term death (Log-Rank=210.8, df =2, p<0.0001). Although in-hospital rates of death and MI are higher following STEMI, the cumulative rates of death (and CVD) were not different, by class of ACS, over the duration of follow-up (Wilcoxon = 1.5597, df=1, p=0.21). At 5yrs after STEMI 269/1403 (19%) died; after non-STEMI 262/1107, (22%) after UA 148/850, (17%). About half (55%) of STEMI deaths occurred after initial hospital discharge, but this was 81% for non-STEMI and 94% for UA.

Conclusions: The GRACE risk score predicts early and 5-year death and CVD/MI. 5-year morbidity and mortality are as high in patients following non-ST MI and UA as seen following STEMI. Their morbidity burden is high (MI, stroke, readmissions) and the substantial late mortality in non-STE ACS is under-recognised. The findings highlight the importance of pursuing novel approaches to diminish long-term risk.

Conclusions:
5-year morbidity and mortality are as high in patients following non-ST MI and UA as seen following STEMI. Their morbidity burden is high (MI, stroke, readmissions) and the substantial late mortality in non-STE ACS is under-recognised. The findings highlight the importance of pursuing novel approaches to diminish long-term risk.



Freek Verheugt, FESC
  Discussant
Discussant | see Presenter abstract Play presentation webcast
Verheugt, Freek
(Netherlands)
Open presentation slides

Report:

Introduction: Long term registries of ACs are hardly available.

GRACE presented 5 year data with a over 99% follow-up complete. Long-term STEMI and NSTEMI mortality is considerable and can be accurately predicted by the GRACE risk score for early risk assessment.

Conclusion: The GRACE risk score is also valuable for long term mortality predicion after ACS. However, the data presented only represent 5-7% of the whole GRACE population. Furthermore, differences in treatment and location on one hand and long-term outcome on the other could also have been presented, as well as differences between the several long-term registries.


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.